作者
Laura Schwarzmueller,R. Adam,Leandro Ferreira Moreno,Lisanne E. Nijman,Adrian Logiantara,Steven Eleonora,Oscar Bril,Sophie P. J. M. Vromans,Nina E. de Groot,Francesca Paola Giugliano,E. N. Stepanova,Vanesa Muncan,Clara C. Elbers,Kristiaan J. Lenos,Danny A. Zwijnenburg,Monique A.J. van Eijndhoven,D. Michiel Pegtel,Sanne M. van Neerven,Fabricio Loayza‐Puch,Tulin Dadali,Wendy Broom,Martin A. Maier,Jan Koster,Milou S. van Driel,Nicolas Léveillé
摘要
Background Aberrant Wnt pathway activation is a key driver of colorectal cancer (CRC) and is essential to sustain tumour growth and progression. Although the downstream protein-coding target genes of the Wnt cascade are well known, the long non-coding transcriptome has not yet been fully resolved. Objective In this study, we aim to comprehensively reveal the Wnt-regulated long non-coding transcriptome and exploit essential molecules as novel therapeutic targets. Design We used global run-on sequencing to define β-catenin-regulated long non-coding RNAs (lncRNAs) in CRC. CRISPRi dropout screens were subsequently used to establish the functional relevance of a subset of these lncRNAs for long-term expansion of CRC. Results We uncovered that LINC02418 is essential for cancer cell clonogenic outgrowth. Mechanistically, LINC02418 regulates MYC expression levels to promote CRC stem cell functionality and prevent terminal differentiation. Furthermore, we developed effective small interfering RNA (siRNA)-based therapeutics to target LINC02418 RNA in vivo . Conclusion We propose that cancer-specific Wnt-regulated lncRNAs provide novel therapeutic opportunities to interfere with the Wnt pathway, which has so far defied effective pharmacological inhibition.